A dietetics professor explains who should and should not embrace the latest weight-loss drugs. Holiday weight gain hits home ...

While weight loss is a common new year's resolution for workers in the U.S., 2025 may mark the year that building weight loss ...

Semaglutide combined with automated insulin delivery enhances glucose control in type 1 diabetes, lowering insulin ...

Pharmacy professor Nicole Albanese discusses the science behind drugs like Ozempic and Wegovy, their potential to treat other ...

Australia is home to some truly unique and unexpected creatures, but few are quite as strange and fascinating as the platypus ...

Investors, startups and insurers are promoting individual coverage health reimbursement arrangements, known as ICHRAs, even ...

Scientists uncover how Ffar4 regulates sugar cravings through gut microbiota, revealing pantothenate as a key mediator to ...

Risk for pancreatitis was not elevated among users of tirzepatide relative to placebo, despite the presence of elevated pancreatic enzymes.

Catalent’s acquisition by Novo Holdings, to help Novo Nordisk meet manufacturing demand for glucagon-like peptide (GLP)-1 obesity medicines, has taken sterile fill-finish capacity out of the market, ...

The series A fundraising is the biggest ever for a European biotech firm, according to the data provider PitchBook.

In the company's third-quarter report in October, Lilly reported sales of both Mounjaro and Zepbound that missed expectations, as wholesalers cut inventory after bulking up on supply in the previous ...

Lexaria Bioscience (LEXX) announces partial final results showcasing the tolerability and glycemic control efficacy findings from human study ...